HEMO+ | Linksium
Back to portfolio

HEMO+

Maturation

Oral medication to treat hemophila

profilePhoto   Valentine Panel
Linksium Contact Valentine Panel +33 (0)6 35 81 73 67 valentine.panel@linksium.fr
190051 M Hemo

Benefits

  • Oral administration
  • Better quality of life for patients
  • Low cost

Key words

  • Hemophilia
  • Molecule repositioning
  • Oral administration

Intellectual Property

  • 1 patent

Laboratories

  • DCM
  • DPM

Institutions

  • CNRS
  • UGA

Linksium Continuum

  • Maturation

Context

Hemophilia is a rare disease due to a deficiency of clotting factor FVIII or FIX depending on whether it is hemophilia A or B. Usually, patients are treated with injection replacement therapy, which generates resistance in approximately 30% of patients.

Technology

We offer the first orally administrable chemical drug based on a repositioning approach.

Advantages

It is a non-invasive, inexpensive treatment that presents little risk of generating antibodies and therefore resistance.

State of progress

Following a screening of existing molecules, a hit has been identified for the coagulation of hemophilia plasma and an optimization work by structural analogy is in progress.

Applications

This treatment would target all types of hemophilia.

Featured articles

Nora Dempsey and deeptech innovations

1, 2 and 3 startups for Nora Dempsey, National Medal of Innovation 2021

Nora Dempsey is one of the four winners of National Medal for Innovation 2021 awarded by CNRS. Nora Dempsey, born in Ireland, has gained an international recognition for her research in Grenoble on...

Read the article
Dd amiral 2018 Frenchweb

Amiral Technologies, la startup IA grenobloise spécialisée dans les solutions de maintenance prédictive, intègre Station F

An ambitious promise: to invent a zero-defect and zero-downtime future for industry. Amiral Technologies, a startup co-founded and boosted by Linksium, based on the technological prowess of the Gre...

Read the article